Eosinophile Ösophagitis
In: Swiss Medical Forum ‒ Schweizerisches Medizin-Forum, Band 8, Heft 39
ISSN: 1424-4020
71 Ergebnisse
Sortierung:
In: Swiss Medical Forum ‒ Schweizerisches Medizin-Forum, Band 8, Heft 39
ISSN: 1424-4020
In: Aktuelle Dermatologie: Organ der Arbeitsgemeinschaft Dermatologische Onkologie ; Organ der Deutschen Gesellschaft für Lichtforschung, Band 29, Heft 11, S. 484-486
ISSN: 1438-938X
In: Aktuelle Dermatologie: Organ der Arbeitsgemeinschaft Dermatologische Onkologie ; Organ der Deutschen Gesellschaft für Lichtforschung, Band 29, Heft 6, S. 243-246
ISSN: 1438-938X
In: Schweizerische Ärztezeitung: SÄZ ; offizielles Organ der FMH und der FMH Services = Bulletin des médecins suisses : BMS = Bollettino dei medici svizzeri
ISSN: 1424-4004
In: Swiss Medical Forum ‒ Schweizerisches Medizin-Forum, Band 5, Heft 28
ISSN: 1424-4020
In: Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie: mit Beiträgen zur Umweltmedizin, Band 72, Heft 6, S. 284-289
ISSN: 2198-0713
ZusammenfassungDie vorliegende Übersicht zum Biomarker "eosinophiles kationisches Protein" wird im Rahmen der Serie "Biomarker" des Zentralblatts für Arbeitsmedizin, Arbeitsschutz und Ergonomie publiziert, die sich mit dem immer häufigeren Gebrauch der Bestimmung von spezifischen Markern bei sog. Manager-Vorsorgen und Check-up-Untersuchungen beschäftigt. Das eosinophile kationische Protein eignet sich grundsätzlich nicht für solche Vorsorgen, sondern ist ein Marker zur Therapieplanung und zum Therapiemonitoring von Asthma. Hier zeigt dieser eine hohe Sensitivität und Spezifität, wobei der Marker aber auf keinen Fall als Screeningparameter zur Frühdiagnostik eingesetzt werden soll.
In: Swiss Medical Forum ‒ Schweizerisches Medizin-Forum, Band 14, Heft 5152
ISSN: 1424-4020
In: Swiss Medical Forum ‒ Schweizerisches Medizin-Forum, Band 15, Heft 42
ISSN: 1424-4020
In: Swiss Medical Forum ‒ Schweizerisches Medizin-Forum, Band 13, Heft 46
ISSN: 1424-4020
Eosinophil-associated gastrointestinal disorders (EGIDs), including eosinophilic esophagitis (EE) and eosinophilic gastroenteritis (EG), are a spectrum of increasingly recognized inflammatory diseases characterized by gastrointestinal symptoms and eosinophilic infiltration of the gastrointestinal tract. Significant morbidity is associated with the development of esophageal strictures in some patients. Immune-mediated reactions to food allergens appear to drive the inflammation in a subset of patients, especially those with solitary EE, but dietary interventions remain difficult in EE and are less effective in EG. Despite the increasing incidence of these disorders and their increased recognition by physicians, there are currently no medications that either United States or European Union regulatory agencies have specifically approved for use in EGIDs. This lack of safe and effective therapies for EGIDs is a major obstacle in the care of these patients and underscores the need for new therapeutic approaches. This review briefly discusses the currently available "off label" drug treatments for EGIDs, most notably topical and systemic corticosteroids. Pathogenesis studies of EGIDs suggest possible therapeutic targets, and conversely, clinical trials of mechanistically-targeted therapeutics give insight into disease pathogenesis. Thus, EGID pathogenesis is discussed as an introduction to mechanistically-targeted immunotherapeutics. The two biologic categories that have been used in EGIDs, anti-IgE (omalizumab) and anti-IL-5 (SCH55700/reslizumab and mepolizumab), are discussed. Since there are similarities in the pathogenesis of EGIDs with asthma and atopic dermatitis, biologic therapeutics currently in early trials for asthma management are also briefly discussed as potential therapeutic agents for EGIDs. Given the deficiencies of current therapeutics and the rapidly advancing knowledge of the pathogenesis of these disorders, EGIDs are an ideal model for translating recent advances in understanding ...
BASE
In: Aktuelle Dermatologie: Organ der Arbeitsgemeinschaft Dermatologische Onkologie ; Organ der Deutschen Gesellschaft für Lichtforschung, Band 43, Heft 7, S. 312-315
ISSN: 1438-938X
ZusammenfassungWir stellen eine 58-jährige Patientin mit disseminierten papulo-pustulösen Hautveränderungen im Gesichts-Halsbereich vor. In der Biopsie zeigte sich eine klassische sog. eosinophile Follikulitis, welche im Verlauf schnell auf die systemische Behandlung mit Antibiotika und lokalem Metronidazol ansprach. Serologisch stellten wir erstmals das Vorliegen einer HIV-Erkrankung fest. Rosazea-artige eosinophile Follikulitiden im Gesichtsbereich können also auch "presenting sign" einer HIV-Infektion sein.
In: Chemical Immunology and Allergy; Angiogenesis, Lymphangiogenesis and Clinical Implications, S. 138-154
In: Sivapalan , P & Jensen , J U 2022 , ' Biomarkers in Chronic Obstructive Pulmonary Disease : Emerging Roles of Eosinophils and Procalcitonin ' , Journal of Innate Immunity , vol. 14 , no. 2 , pp. 89-97 . https://doi.org/10.1159/000517161
Antibiotics can improve the prognosis in patients with exacerbation of chronic obstructive pulmonary disease. However, the overuse of antibiotics can carry serious adverse effects for patients (gastrointestinal infections) and for society (bacterial resistance). Likewise, systemic corticosteroids may also help these patients, but also carries severe adverse effects like osteoporosis, muscle loss, and diabetes, in many patients. Whenever safe methods exist to reduce these two treatment modalities, they should be implemented. The blood biomarkers procalcitonin and the fraction of leukocytes known as eosinophil granulocytes have been proven in randomized controlled trials (RCTs), to effectively, significantly, and substantially assist in reducing the use of these two potent, yet toxic medication types. In this review, the background and main clinical results are discussed, explaining the rationale for biomarker-guided clinical decisions. Also, the main expected effects, their sizes, and importantly the limitations to such a strategy are described. Clinical evidence is prioritized with main weight on RCTs and meta-analyses of these and regarding outcomes, and focus is set on the safety of such a biomarker-guided strategy, as well as the effects on medicine reduction. In an epoch of increasing demands to physicians from patients and politicians to cure and reduce symptoms, the Hippocratic phrase of "primum non nocere"or "first, do no harm"seems more than ever of contemporary importance.
BASE
In: info:eu-repo/semantics/altIdentifier/doi/10.2147/COPD.S179734
Yeon-Mok Oh,1,* Keu Sung Lee,2,* Yoonki Hong,3,* Sung Chul Hwang,2 Jae Yeol Kim,4 Deog Keom Kim,5 Kwang Ha Yoo,6 Ji-Hyun Lee,7 Tae-Hyung Kim,8 Seong Yong Lim,9 Chin Kook Rhee,10 Hyoung Kyu Yoon,11 Sang Yeub Lee,12 Yong Bum Park,13 Jin Hee Jung,14 Woo Jin Kim,3 Sang-Do Lee,1 Joo Hun Park2 1Department of Pulmonary and Critical Care Medicine and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; 2Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, Korea; 3Department of Internal Medicine and Environmental Health Center, Kangwon National University, Kangwon National University Hospital, Chuncheon, Korea; 4Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea; 5Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea; 6Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea; 7Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea; 8Division of Pulmonology, Department of Internal Medicine, Hanyang University College of Medicine, Guri, Korea; 9Division of Pulmonary and Critical Care Medicine, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea; 10Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St Mary's Hospital, Catholic University of Korea, Seoul, Korea; 11Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University Anam Hospital, Seoul, Korea; 12Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University Anam Hospital, Seoul, Korea; 13Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital, Seoul, Korea; 14Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea *These authors contributed equally to this work Background: High blood eosinophil count is a predictive biomarker for response to inhaled corticosteroids in prevention of acute exacerbation of COPD, and low blood eosinophil count is associated with pneumonia risk in COPD patients taking inhaled corticosteroids. However, the prognostic role of blood eosinophil count remains underexplored. Therefore, we investigated the associated factors and mortality based on blood eosinophil count in COPD.Methods: Patients with COPD were recruited from 16 hospitals of the Korean Obstructive Lung Disease cohort (n=395) and COPD in Dusty Area cohort (n=234) of Kangwon University Hospital. The two merged cohorts were divided based on blood eosinophil count into three groups: high (≥5%), middle (2%–5%), and low (<2%).Results: The high group had longer six-minute walk distance (high =445.8±81.4, middle =428.5±88.0, and low =414.7±86.3 m), higher body mass index (23.3±3.1, 23.1±3.1, and 22.5±3.2 kg/m2), lower emphysema index (18.5±14.1, 22.2±15.3, and 23.7±16.3), and higher inspiratory capacity/total lung capacity ratio (32.6±7.4, 32.4±9.2, and 29.9% ± 8.9%) (P<0.05). The survival period increased with increasing blood eosinophil count (high =9.52±0.23, middle =8.47±1.94, and low =7.42±0.27 years, P<0.05). Multivariate linear regression analysis revealed that the emphysema index was independently and negatively correlated with blood eosinophil count (P<0.05).Conclusion: In COPD, the severity of emphysema was independently linked with low blood eosinophil count and the longer survival period was associated with increased blood eosinophil count, though it was not proven in the multivariate analysis. Keywords: blood eosinophil, COPD, biomarker
BASE
Background: Study was conducted in school children to reveal the toxic effects of pyrethroids which causes allergic reactions with in the body especially altered lung function tests and eosinophil count.Objective: In the present study, the effects of pyrethroids on eosinophil count of school children were analyzed.Methodology: The present study is a cross-sectional analytical study. The study was conducted at Government Girls Primary School, Sita Nagar, Karachi including 50 children with ages between 6 – 10 years. They were divided equally into two groups: group A (exposed to insecticidal spray) and group B (exposed to mosquito coil). The correlations between the insecticides (Pyrethroids), and eosinophil by linear regression analysis confirmed that insecticides (Pyrethroids) had a strong correlation with the eosinophil count under study exemplified by the significant increase in Eosinophil count was observed after exposure to mosquito coil whereas there was no association between insecticidal spray and Eosinophil count. Results: There was significant increase in Eosinophil count after exposure to mosquito coil whereas no association was observed between insecticidal spray and Eosinophil count.Conclusions: The use of spray over the coil is less hazardous to the health.
BASE